Publication Name	World Journal of Cardiology
Manuscript ID	11325
Country	India

Received	2014-05-15 20:25
Peer-Review Started	2014-05-15 23:03
To Make the First Decision	2014-06-27 12:03
Return for Revision	2014-07-04 12:13
Revised	2014-07-07 15:10
Second Decision	2014-08-31 16:59
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2014-08-31 17:16
Articles in Press	2014-08-31 17:16
Publication Fee Transferred
Edit the Manuscript by Language Editor	2014-09-03 20:39
Typeset the Manuscript	2014-10-27 14:59
Publish the Manuscript Online	2014-11-05 09:45

ISSN	1949-8462 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Cardiac & Cardiovascular Systems
Manuscript Type	Review
Article Title	Mitochondria-targeted agents: Future perspectives of mitochondrial pharmaceutics in cardiovascular diseases
Manuscript Source	Invited Manuscript
All Author List	Thekkuttuparambil Ananthanarayanan Ajith and Thankamani Gopinathan Jayakumar
Funding Agency and Grant Number
Corresponding Author	Thekkuttuparambil Ananthanarayanan Ajith, PhD, Professor, Department of Biochemistry, Amala Institute of Medical Sciences, Amala Nagar, Thrissur 680 555, Kerala, India. taajith@rediffmail.com
Key Words	Cardiovascular diseases; Oxidative stress; Antioxidant; Electron transport chain; Mitochondrial medicine; Heart failure
Core Tip	Dysfunction of mitochondria increases the risk for a large number of human diseases, including cardiovascular diseases. Heart failure (HF) following ischemic heart disease, infantile cardiomyopathy and cardiac hypertrophy associated with left ventricular dilations are some of the cardiovascular diseases in which the role of mitochondrial oxidative stress has been reported. Recent reports on chronic HF followed by ischemic heart disease suggested a reduced supply of energy necessary for the contractile function of cardiomyocytes. Since mitochondrial damages are central to the pathophysiology of HF, various approaches are used to target compounds at mitochondria alone or adjunct to standard therapies.
Publish Date	2014-11-05 09:45
Citation	Ajith TA, Jayakumar TG. Mitochondria-targeted agents: Future perspectives of mitochondrial pharmaceutics in cardiovascular diseases. World J Cardiol 2014; 6(10): 1091-1099
URL	http://www.wjgnet.com/1949-8462/full/v6/i10/1091.htm
DOI	http://dx.doi.org/10.4330/wjc.v6.i10.1091

Full Article (PDF)	WJC-6-1091.pdf
Full Article (Word)	WJC-6-1091.doc
Manuscript File	11325-Review.doc
Answering Reviewers	11325-Answering reviewers.pdf
Copyright License Agreement	11325-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	11325-Language certificate.pdf
Peer-review Report	11325-Peer review(s).pdf
Scientific Misconduct Check	11325-CrossCheck.jpg
Scientific Editor Work List	11325-Scientific editor work list.pdf